Cell therapy KYV-101 put on FDA fast track as MG treatment
KYV-101, an experimental cell therapy for myasthenia gravis (MG) in development by Kyverna Therapeutics, has been granted fast…
Articles by Marisa Wexler, MS
New generic version of Mestinon as oral syrup available in U.S.
A new generic formulation of pyridostigmine bromide — a muscle-strengthening medication sold under the brand name Mestinon — is…
Under-the-skin Vyvgart approved in Europe for AChR-positive gMG
A new under-the-skin injectable formulation of Vyvgart (efgartigimod alfa) has been approved by the European Commission for adults with…
Kyverna to conduct Phase 2 trial of cell therapy KYV-101 in MG
The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application from Kyverna Therapeutics, giving…
Cabaletta cleared to launch Phase 1/2 trial of cell therapy for gMG
The U.S. Food and Drug Administration (FDA) has given Cabaletta Bio the go-ahead to launch a Phase 1/2 clinical…
Zilucoplan, now Zilbrysq, approved by FDA for AChR-positive gMG
The U.S. Food and Drug Administration (FDA) has approved zilucoplan, a once-daily injection therapy to now be marketed under…
GRO Biosciences’ ProGly platform shows promise in MG animal model
A treatment based on GRO Biosciences‘ ProGly program — which uses specially designed proteins to regulate the immune system…
Japan approves zilucoplan, Rystiggo for adults with hard-to-treat gMG
UCB’s zilucoplan and Rystiggo (rozanolixizumab) both were approved in Japan to treat adults with generalized myasthenia gravis…
Povetacicept shows promise in MG mouse model
Treatment with the experimental therapy povetacicept (ALPN-303) reduced disease activity in a mouse model of myasthenia gravis (MG), according…
Elderly MG patients at high risk of treatment side effects
Elderly people with myasthenia gravis (MG) are at higher risk of experiencing side effects related to disease treatments,…